Novo Nordisk’s NVO shares lost 5.3% on Friday after Medicare issued a press release selecting the company’s popular ...

Official data shows that since 2019, this medication has been linked to 23 deaths and 1,179 serious adverse reactions in the ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity ...

Injectable GLP-1 agonists help people struggling to lose weight. Patients are finding the drug also helps reduce recurring ...

Semaglutide, a medication originally designed to treat type 2 diabetes, has recently gained significant attention as a weight ...

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

Semaglutide (known by its brandname Ozempic) has gained widespread attention for its weight loss benefits, but is officially ...